Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees


Nitrogen containing hetero ring

Subclass of:

514 - Drug, bio-affecting and body treating compositions

514001000 - DESIGNATED ORGANIC ACTIVE INGREDIENT CONTAINING (DOAI)

514023000 - Carbohydrate (i.e., saccharide radical containing) DOAI

514042000 - N-glycoside

Patent class list (only not empty are listed)

Deeper subclasses:

Class / Patent application numberDescriptionNumber of patent applications / Date published
514044000 Polynucleotide (e.g., RNA, DNA, etc.) 2020
514045000 Purines (including hydrogenated) (e.g., adenine, guanine, etc.) 315
514049000 Pyrimidines (including hydrogenated) (e.g., cytosine, etc.) 251
514052000 Phosphorus containing (e.g., Vitamin B12, etc.) 69
Entries
DocumentTitleDate
20090192099PRODRUGS OF HETEROARYL COMPOUNDS - The present invention provides hydrophobic prodrugs of bases, nucleosides, and nucleotides as well as methods of using the prodrugs as antiviral and anti-cancer chemotherapeutic agents.07-30-2009
20130085115COMBINATION THERAPY FOR LYMPHOMA - Methods of treating, preventing or managing lymphomas are disclosed. The methods encompass the administration of an HDAC inhibitor romidepsin and a DNA demethylating agent 5-azacitidine, also known as VIDAZA®. Pharmaceutical compositions and single unit dosage forms suitable for use in the methods provided herein are also disclosed04-04-2013
20120245116Inhibiting GS-FDH to Modulate No Bioactivity - Patients needing NO donor therapy or inhibition of pathologically proliferating cells or increased NO bioactivity are treated with a therapeutically effective amount of an inhibitor of glutathione-dependent formaldehyde dehydrogenase.09-27-2012
20090048190Antiviral activity and resolution of 2-hydroxymethyl-5(5-fluorocytosin-1-yl)-1,3-oxathiolane - A method and composition for the treatment of HIV and HBV infections in humans is disclosed that includes administering an effective amount of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane, a pharmaceutically acceptable derivative thereof, including a 5′ or N02-19-2009
20090318379Statins for the Treatment of Viral Influenza Infections - The present invention relates to methods for the treatment of viral influenza using statins, or pharmaceutically effective salts, pro-drugs or metabolites thereof. In particular it is disclosed that statin hydroxyl acid salts including, but not limited to, mevastatin, lovastatin, pravastatin and simvastatin, are effective in conferring resistance to infection with influenza type A viral challenge.12-24-2009
20130090298Thiazole Derivatives as SGLT2 Inhibitors and Pharmaceutical Composition Comprising Same - The present invention relates to a novel compound with thiazole ring having an inhibitory activity against sodium-dependent glucose cotransporter 2 (SGLT2) being present in the intestine and kidney, and a pharmaceutical composition comprising the same as an active ingredient, which is useful for preventing or treating metabolic disorders, particularly diabetes.04-11-2013
20130059810PHARMACEUTICAL COMPOSITIONS COMPRISING FORMS OF 5-AZACYTIDINE - The invention provides novel polymorphic and pseudopolymorphic crystalline forms of 5-azacytidine, along with methods for preparing said forms, wherein 5-azacytidine is represented by the formula:03-07-2013
20130059809PHARMACEUTICAL COMPOSITIONS COMPRISING FORMS OF 5-AZACYTIDINE - The invention provides novel polymorphic and pseudopolymorphic crystalline forms of 5-azacytidine, along with methods for preparing said forms, wherein 5-azacytidine is represented by the formula:03-07-2013
20090012015LARGE DOSE RIBAVRIN FORMULATONS - The present invention is related to pharmaceutical dosage forms of ribavirin which are designed to increase patient compliance to a ribavirin therapy. Examples of such dosage forms include 400 mg to 600 mg tablets. These dosage forms are bioequivalent to multiple doses of tablets containing small amounts of ribavirin.01-08-2009
20120115804COMPOSITIONS AND METHODS FOR CHARACTERIZING AND TREATING NEOPLASIA - The invention features compositions and methods for characterizing the methylation status of the Vitamin D Receptor (VDR) in neoplasia (e.g., breast carcinoma), selecting an appropriate therapy, and treating the neoplasia (e.g., breast carcinoma).05-10-2012
20100279967COMPOSITIONS AND METHODS FOR TREATING CANCER - Provided herein are methods of treating cancer comprising administering decitabine in combination with compounds that inhibit the deamination enzyme responsible for the inactivation of decitabine.11-04-2010
20100216733Use of inhibitors and antisense oligonucleotides of btk for treating proliferative mastocytosis - The present invention relates to a method for treating proliferative mastocytosis comprising administering a Bruton tyrosine kinase (BTK) inhibitor, a BTK antisense to a mammal in need of such treatment. The invention is more particularly suited for treating category II, III and IV mastocytosis.08-26-2010
20090099106QUINOLINE DERIVATIVES FOR MODULATING DNA METHYLATION - Quinoline derivatives, particularly 4-anilinoquinoline derivatives, are provided. Such quinoline derivatives can be used for modulation of DNA methylation, such as effective inhibition of methylation of cytosine at the C-5 position, for example via selective inhibition of DNA methyltransferase DNMT1. Methods for synthesizing numerous 4-anilinoquinoline derivatives and for modulating DNA methylation are provided. Also provided are methods for formulating and administering these compounds or compositions to treat conditions such as cancer and hematological disorders.04-16-2009
20110144048Novel Uses of Neuraminidase Inhibitors in Infectious Diseasess - The present invention relates to methods of decreasing the infectivity, morbidity and rate of mortality, in treating diseases associated with a variety of pathogenic organisms, specifically diseases involving one or more pathogens that require neuraminidase as a virulence factor. In addition, the present invention uses biology based therapy to treat neuraminidase dependent infections or diseases dependent on sialic acid metabolism.06-16-2011
20080293651CYTOSINE NUCLEOSIDE ANALOGS AND ISOFLAVONES AND USES THEREOF - Methods, uses, compositions and kits relating to the inhibition and/or prevention of undesirable cell proliferation, and prevention and/or treatment of diseases or disorders associated with such proliferation, such as cancer, using a cytosine nucleoside analog and an isoflavone, are described.11-27-2008
20110301110TRIM33 (TIF1gamma) AS A NEW DIAGNOSTIC MARKER OF CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML) - A method for diagnosing a chronic myelomonocytic leukemia (CMML) in a subject includes the steps of (i) determining the level of expression of the Trim33 (tripartite motif-containing 33) gene in a biological sample from the subject, and (ii) comparing the level of expression of the Trim33 gene in the biological sample with its normal level of expression; wherein an under-expression of the Trim33 gene is associated with CMML, and to a kit for diagnosing CMML in a subject including at least one nucleic acid probe or oligonucleotide or at least one antibody, which can be used in a such a method.12-08-2011
20110288042STABLE HIGHLY PURE AZACITIDINE AND PREPARATION METHODS THEREFOR - Disclosed herein are methods of obtaining highly pure 5-azacytidine, which contains minimal amounts of degradation impurities and methods of assessing the impurity profile of the degradation of cytidine analogues, such as 5-azacytidine11-24-2011
20080293650Fused Heterocyclic Compounds and Use Thereof - Fused heterocylic compounds of the following Formula11-27-2008
20100069318COMBINATION OF AN HDAC INHIBITOR AND AN ANTIMETABOLITE - The invention relates to a combination which comprises: 03-18-2010
20090149400ANTI-PROLIFERATIVE COMPOUNDS, COMPOSITIONS, AND METHODS OF USE THEREOF - Compounds and compositions of Formula I are described, useful as anti-proliferative agents, and in particular anti-HPV,06-11-2009
20090247481Compositions and Kits for Treating Influenza - Compositions, kits and methods are provided for the treatment or prophylaxis of influenza.10-01-2009
20090088397INHIBITORS OF SECRETION OF HEPATITIS B VIRUS ANTIGENS FOR TREATMENT OF A CHRONIC HEPATITIS VIRUS - A pharmaceutical composition comprising an effective amount of a compound of formulas (I-III) and a pharmaceutically acceptable carrier. Methods for treating a hepatitis virus in a patient comprising administering an effective amount of the compound of formulas (I-III) are also presented.04-02-2009
20090286752ORAL FORMULATIONS OF CYTIDINE ANALOGS AND METHODS OF USE THEREOF - The present disclosure provides pharmaceutical compositions comprising cytidine analogs for oral administration, wherein the compositions release the cytidine analog substantially in the stomach. Also provided are methods of treating diseases and disorders using the oral formulations provided herein.11-19-2009
20090042823USES OF BROAD SPECTRUM RNAI THERAPEUTICS AGAINST INFLUENZA - Methods and uses of RNAi-inducing agents for medicaments and treating or preventing a viral infection.02-12-2009
20090042822METHOD TO ENHANCE DELIVERY OF GLUTATHIONE AND ATP LEVELS IN CELLS - A therapeutic method is provided comprising treating a mammal subject to hypoxia with an amount of 2(R,S)-D-ribo-(1′,2′,3′,4′-tetrahydroxybutyl)thiazolidine-4(R)-carboxylic acid (RibCys) or a pharmaceutically acceptable salt thereof effective to both maintain, restore or increase both the ATP levels and the glutathione (GSH) levels in said tissue.02-12-2009
20090042821STABLE DOSAGE FORMS OF SPIRO AND DISPIRO 1,2,4-TRIOXOLANE ANTIMALARIALS - The field of the invention relates to stable dosage forms comprising spiro or dispiro 1,2,4-trioxolane antimalarials, or their pharmaceutically acceptable salts, prodrugs and analogues, and processes for their preparation. The water content of the dosage form is not more than 6.5% w/w.02-12-2009
20110269705QUINOLONE COMPOUND AND PHARMACEUTICAL COMPOSITION - The present invention provides a quinolone compound that inhibits the chronic progression of Parkinson's disease or protects dopamine neurons from disease etiology, thereby suppressing the progression of neurological dysfunction, so as to prolong the period of time until L-dopa is administered while also improving neuronal function; the quinolone compound of the invention is represented by Formula (1):11-03-2011
20100137236Compositions Comprising a GPR109 Ligand For Treating Disorders of the Digestive Tract and/or Cancer - Pharmaceutical compositions containing an effective amount of a ligand for GPR109 to decrease intracellular cAMP levels of a subject in combination with an effective amount of a DNA methyl transferase inhibito to reduce or inhibit downregulation of GPR109 in the intestinal epithelial cells of the subject relative to a control are provided. It has been discovered that ligands for GPR109 can be used to treat one or more symptoms of cancer, inflammatory disorders, and diarrhea. Representative CPR 109 ligands include, but are not limited to butyrate, β-hydroxybutyrate, nicotinic acid, acifran, and octanoate. Suitable DNA methyl transferase inhibitors include 5-azacytidine, 5-aza-2′-deoxytidine, 1-β-D-arabinfαmosyl-5-azacytosine and dihydro-5-azacytidine. Typically, the compositions are formulated to achieve a GPR 109 ligand serum blood level of about 1 to about 1000 μM. The compositions are useful for the treatment of one or more symptoms of cancer. Preferred cancers that can be treated using the disclosed compositions include, but are not limited to colon cancer, breast cancer and leukemia. Methods for treating cancer, inflammatory disorders, and diarrhea are also provided.06-03-2010
20080280842Fluorinated Pyrrolo[2,3-D]Pyrimidine Nucleosides for the Treatment of Rna-Dependent Rna Viral Infection - The present invention provides fluorinated pyrrolo[2,3,d]pyrimidine nucleoside compounds which are inhibitors of RNA-dependent RNA viral polymerase. These compounds are inhibitors of RNA-dependent RNA viral replication and are useful for the treatment of RNA-dependent RNA viral infection. They are particularly useful as precursors to inhibitors of hepatitis C virus (HCV) NS5B polymerase, as precursors to inhibitors of HCV replication, and/or for the treatment of hepatitis C infection. The invention also describes pharmaceutical compositions containing such fluorinated pyrrolo[2,3-d]pyrimidine nucleoside alone or in combination with other agents active against RNA-dependent RNA viral infection, in particular HCV infection. Also disclosed are methods of inhibiting RNA-dependent RNA polymerase, inhibiting RNA-dependent RNA viral replication, and/or treating RNA-dependent RNA viral infection with the fluorinated pyrrolo[2,3-d]pyrimidine nucleoside of the present invention.11-13-2008
20080287378Solid state forms of 5-azacytidine and processes for preparation thereof - The present invention provides novel crystalline forms of 5-deazacytidine, and pharmaceutical compositions comprising these novel forms. The invention also provides methods for the preparation of the novel forms and compositions.11-20-2008
20100292180Pharmaceutical Compositions Comprising Crystal Forms of 5-Azacytidine - The invention includes methods for isolating crystalline Form I of 5-azacytidine substantially free of other forms, wherein 5-azacytidine is represented by the formula:11-18-2010
20090042820Tubulin Binding Anti Cancer Agents And Prodrugs Thereof - Novel tubulin binding compounds and hypoxia activated prodrugs of novel and known tubulin binding compounds useful for treating cancer and other hyperproliferative diseases are disclosed.02-12-2009
20090036391Modulation of line-1 reverse transcriptase - A reverse transcriptase encoded by L-1 (LINE-1) has been identified as a target molecule for treating or preventing cancers induced or mediated by this molecule. Method of treating or preventing such cancers in patients involves administration of a therapeutically effective amount of a composition having an inhibitor or antagonist of the reverse transcriptase in cells of the patients. The inhibitor or antagonist blocks lengthening of telomeres in telomerase negative cells. Methods and kits for detecting pathologically proliferating cells expressing L1RT are also disclosed.02-05-2009
20090247480Anti-cancer therapies - Methods for the treatment of cancer are described. In particular, methods for treatment of cancer comprising administration of glufosfamide alone or in combination with another anticancer agent are disclosed.10-01-2009
20090023669Antibacterial Agents - The present invention, in one aspect, provides a method of inhibiting bacterial growth by contacting bacteria with an effective amount of at least one monosaccharide compound of formula (1) as described herein:01-22-2009
20090054358Flt3 inhibitors for immune suppression - New methods are provided for suppressing the immune system and for treating immune related disorders. Therapies of the invention include administration of an FLT3 inhibitor compound to a subject in need thereof, such as a subject suffering from organ rejection, bone marrow transplant rejection, acquired immune deficiency syndrome, arthritis, aplastic anemia, graft-versus-host disease, Graves' disease, established experimental allergic encephalitomyelitis, multiple sclerosis, lupus, or a neurological disorder. Methods are also provided for screening therapeutic agents for treating immune disorders, including the use of a mouse having an elevated level of FLT3 receptor activity.02-26-2009
20090062223AMINO TRICYCLIC-NUCLEOSIDE COMPOUNDS, COMPOSITIONS, AND METHODS OF USE - Provided are compounds of Formula (I) or a pharmaceutically acceptable salt or solvate thereof. The compounds and compositions are useful for treating viral infections caused by the Flaviviridae family of viruses.03-05-2009
20090054360Method and Composition for Treating Allergic Diseases - A method and composition for treating allergic diseases and/or airway inflammation including pollinosis, bronchial asthma, allergic rhinitis, atopic dermatitis and anaphylactic shock with the administration to a subject an amount of an anti-infectious agent such as ribavirin and optionally combined with an anti-inflammatory agent selected from inhaled steroids, leukotriene receptor antagonists and beta-02-26-2009
20090054359COMPOSITIONS AND THEIR USES DIRECTED TO DIACYLGLYCEROL ACYLTRANSFERASE 1 - Disclosed herein are compounds, compositions and methods for modulating DGAT-1 activity. Preferably, the expression of DGAT-1 from a nucleic acid is inhibited. Methods are provided for treating, ameliorating or treating liver fibrosis, either directly or by treating an underlying etiological factor. Preferably, the treatment, amelioration or prevention comprises administering a DGAT-1 activity modulator.02-26-2009
20110230432COMPOSITIONS AND KITS FOR TREATING INFLUENZA - Compositions, kits and methods are provided for the treatment or prophylaxis of influenza.09-22-2011
20090005328METHODS OF MODULATING TUBULIN DEACETYLAST ACTIVITY - The present invention provides methods for identifying agents that modulate a level or an activity of tubulin deacetylase polypeptide, as well as agents identified by the methods. The invention further provides methods of modulating tubulin deacetylase activity in a cell. The invention further provides methods of modulating cellular proliferation by modulating the activity of tubulin deacetylase.01-01-2009
20090099105Content dependent inhibitors of cytidine deaminases and uses thereof - This invention relates to cytidine deaminase inhibitors (Cytidine deaminase inhibitors) of cytidine deaminases and uses thereof.04-16-2009
20120196824THERAPEUTIC AGENT FOR CEREBRAL INFARCTION - The invention provides a therapeutic drug for ischemic stroke. The therapeutic drug has the formula (I)08-02-2012
20100261666COMPOSITIONS AND METHODS FOR THE TREATMENT OF MYOCARDIAL DYSFUNCTION ASSOCIATED WITH SIRS OR SEPSIS - Provided are compositions and methods for the treatment of myocardial dysfunction associated with SIRS or sepsis, which methods comprise the administration to a patient in need thereof of a composition comprising one or more adenosine deaminase (ADA) inhibitor and/or one or more xanthine oxidase (XO) inhibitor. Exemplified herein are methods for the treatment of myocardial dysfunction, which methods comprise the administration of a composition comprising the ADA inhibitor pentostatin and/or a composition comprising the XO inhibitor allopurinol. Advantageously, the methods disclosed herein that employ the administration of one or more ADA inhibitor(s) do not significantly affect cardiac TNF-α mRNA expression and/or protein levels.10-14-2010
20090048189TRICYCLIC-NUCLEOSIDE COMPOUNDS FOR TREATING VIRAL INFECTIONS - Disclosed are tricyclic nucleoside compounds of formula (I), and methods thereof for treating viral infections mediated at least in part by a Flaviviridae family virus.02-19-2009
20130123207Compositions Containing Resveratrol and Nucleotides - A resveratrol-containing composition capable of providing a therapeutic benefit to a subject such as modulation of a biological activity, improving cell transplantation therapy, or improving macular degeneration or dystrophy treatments. The compositions comprise trans-resveratrol, a metal chelator, one or more additional antioxidants such as quercetin, gamma-tocotrienol, or apple polyphenols, allicin, and nucleotides.05-16-2013
20100216734MODULATION OF NEUROGENESIS BY NOOTROPIC AGENTS - The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The disclosure includes compositions and methods based on use nootropic agents, optionally in combination with one or more other neurogenic agents, to stimulate or activate the formation of new nerve cells.08-26-2010
20090075920DEUTERIUM-ENRICHED DECITABINE - The present application describes deuterium-enriched decitabine, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.03-19-2009
20120196823PHARMACEUTICAL COMPOSITIONS OF CYTIDINE ANALOGS AND METHODS OF USE THEREOF - The present disclosure provides pharmaceutical compositions comprising cytidine analogs for parenteral administration. Also provided are methods of preparing the compositions and methods of treating diseases and disorders using the compositions provided herein.08-02-2012
20090281052Indole Antiviral Compositions And Methods - The present invention provides novel chemical compounds, and methods for their use. In particular, the present invention provides indole derivatives (e.g. as shown in Formula (I)) and related compounds and methods of using indole derivatives and related compounds as therapeutic agents to treat a number of conditions, including those associated with viral infection and cardiovascular diseases.11-12-2009
20090197823ALISKIREN MODULATION OF NEUROGENESIS - The disclosure provides compositions and methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis by use of a renin inhibitor in combination with one or more neurogenic agents. The disclosure also includes compositions and methods for stimulating or activating the formation of new nerve cells based on the application of a renin inhibitor in combination with one or more neurogenic agents.08-06-2009
20100305059COMPOSITION AND METHODS FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROME AND ACUTE MYELOID LEUKEMIA - Methods and compositions are provided for treating myelodysplastic syndrome and acute myeloid leukemia, wherein the composition comprises at least one compound according to Formula I:12-02-2010
20110039797Oligomer Conjugates of Heteropentacyclic Nucleosides - The invention provides small molecule drugs that are chemically modified by covalent attachment of a water-soluble oligomer.02-17-2011
20110118203Novel Crystalline Forms Of An Antiviral Benzimidazole Compound - The invention relates to crystalline forms of 5,6-dichloro-2-(isopropylamino)-1-β-L-ribofuranosyl-1Hbenzimidazole, pharmaceutical compositions comprising the same, processes for preparing the same, and their use in medical therapy.05-19-2011
201002860815-AMINO-3-(2',3'-DI-O-ACETYL-BETA-D-RIBOFURANOSYL)-3H-THIAZOLO[4,5-D] PYRIMIDIN-2-OCE SALTS AND CRYSTALLINE FORMS - The invention relates to a maleate salt of 5-amino-3-(2′-3′-di-O-acetyl-beta-D-ribofuranosyl)-3H-thiazolo[4,5-d]pyrimidin-2-one and crystalline forms thereof, their production and usage, and pharmaceutical preparations containing these crystalline forms.11-11-2010
20110124591COMPOUNDS AND METHODS FOR MODULATING PROTEIN EXPRESSION - The present invention provides compounds and methods for modulating expression of a protein, including, but not limited to, modulating splicing of a pre-mRNA to modulate the amount of one or more variants of a protein.05-26-2011
20110098242Methods and Compositions for Diagnosing and Treating Cervical Intraepithelial Neoplasia and Cervical Cancer - Disclosed herein are methods and compositions for diagnosing and treating diseases associated with a loss of cystatin E/M expression including cervical intraepithelial neoplasia and cervical cancer. Genetic mutations and exonic deletions which result in a loss of cystatin E/M expression are also disclosed.04-28-2011
20110098241RAPAMYCIN ANALOGS AS ANTI-CANCER AGENTS - Analogs and derivatives of rapamycin are provided, wherein the analogs and derivatives can bind to FK-506 binding protein (FKBP), or inhibit the mTOR function of an FKBP, or both. The analogs and derivatives are rapamycin include the rapamycin skeleton substituted at the 42-hydroxyl group with certain specified chemically feasible groups. Methods of using the rapamycin analogs and derivatives in treatment of malconditions such as cancer, and methods of synthesizing the rapamycin analogs and derivatives, are provided.04-28-2011
20110251149METHODS AND LOW DOSE REGIMENS FOR TREATING RED BLOOD CELL DISORDERS - Disclosed herein are methods and low dose regimens for increasing fetal hemoglobin levels in patients with red blood cell disorders, such as beta thalassemia, sickle cell disease, other anemias, or blood loss. Fetal and total hemoglobin levels and red blood cell counts are increased by administering 2,2-dimethylbutyrate (DMB) alone or in combination with hydroxyurea, decitabine or an HDAC inhibitor. Treatment can be continued for at least two weeks.10-13-2011
20100279966COMPOSITIONS AND METHODS FOR TREATING CANCER - Provided herein are compounds used to inhibit the deamination enzyme responsible for the inactivation of therapeutic compounds, and methods of using them.11-04-2010
20100261665Kinase inhibitor compounds - The invention relates to compounds, compositions comprising the compounds, and methods of using the compounds and compound compositions. The compounds, compositions, and methods described herein can be used for the therapeutic modulation of kinase-mediated processes, and treatment of disease and disease symptoms, particularly those mediated by certain kinase enzymes.10-14-2010
20130165398CONCENTRATION-ENHANCING DRINK - A concentration-enhancing drink contains, in each case independently of one another, per liter: 1 mg to 10 g, preferably 1 to 1000 mg, still more preferably 10 to 500 mg, in particular 50 to 300 mg, of epigallocatechin gallate; 1 to 500 mg, preferably 10 to 100 mg, in particular 20 to 80 mg, of nicotinamide ribose; and/or 0.05 to 10 g, preferably 0.1 to 5 g, in particular 0.5 to 3 g of tryptophan.06-27-2013
20120202763METHODS FOR TREATING CANCER AND NON-NEOPLASTIC CONDITIONS - Compounds that selectively inhibit pathological production of human vascular endothelial growth factor (VEGF) and compositions comprising such Compounds are described. Compounds that inhibit viral replication or the production of viral RNA or DNA or viral protein and compositions comprising such Compounds are described. Also described are methods of reducing VEGF using such Compounds and methods for treating cancer and non-neoplastic conditions involving the administration of such Compounds. Further described are methods of inhibiting viral replication or the production of viral RNA or DNA or viral protein using such Compounds and methods for treating viral infections involving the administration of such Compounds. The Compounds may be administered as a single agent therapy or in combination with one or more additional therapies to a human in need of such treatments.08-09-2012
20110178038Indole Antiviral Compositions And Methods - The present invention provides novel chemical compounds, and methods for their use. In particular, the present invention provides indole derivatives (e.g. as shown in Formula (I)) and related compounds and methods of using indole derivatives and related compounds as therapeutic agents to treat a number of conditions, including those associated with viral infection and cardiovascular diseases.07-21-2011
20110053882METHODS AND COMPOUNDS FOR PREVENTING AND TREATING A TUMOUR - The invention relates to a method of preventing, inhibiting, arresting or reversing tumourigenesis in a cell as well as a method of inducing apoptosis in a tumour cell. The method includes increasing the amount and/or the activity of a DACT protein, or a functional fragment thereof, in the cell. Also provided is a pharmaceutical composition that comprises a compound of general formula (I), wherein A is CH or N, R03-03-2011
201100538816-Disubstituted Or Unsaturated Bicyclic Nucleic Acid Analogs - The present disclosure describes 6-disubstituted bicyclic nucleosides, oligomeric compounds prepared therefrom and methods of using the oligomeric compounds. More particularly, the 6-disubstituted bicyclic nucleosides each comprise a 2′-O—C(Ri)(R2)-4′ or 2′-O—C=(R3)(R.4)-4′ bridge wherein each R is, independently a substituent group and Ri and R2 include H. The 6-disubstituted bicyclic nucleosides are useful for enhancing properties of oligomeric compounds including nuclease resistance. In certain embodiments, the oligomeric compounds provided herein hybridize to a portion of a target RNA resulting in loss of normal function of the target RNA.03-03-2011
20110263523TET2 AS A NEW DIAGNOSTIC AND PRONOSTIC MARKER IN HEMATOPOIETIC NEOPLASMS - The present invention concerns an in vitro method for diagnosing a myeloid tumour or a lymphoid tumour in a subject, which comprises the step of analyzing a biological sample from said subject by (i) detecting the presence of a mutation in the Ten Eleven Translocation protein family member 2 gene (TET2) coding for the polypeptide having the sequence SEQ ID NO:2, and/or (ii) analyzing the expression of the TET2 gene; wherein the detection of such a TET2 mutation, of the absence of expression of TET2 or of the expression of a truncated TET2 is indicative of a subject developing or predisposed to develop a myeloid tumour or a lymphoid tumour.10-27-2011
20100298253Pharmaceutical Compositions Comprising Forms of 5-Azacytidine - The invention provides novel polymorphic and pseudopolymorphic crystalline forms of 5-azacytidine, along with methods for preparing said forms, wherein 5-azacytidine is represented by the formula:11-25-2010
20110136754NOVEL TRIAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPEUTICS - The present invention relates to novel compounds of formula (A):06-09-2011
20110136753GLYCOSYLATED INDOLECARBAZOLES, METHOD FOR OBTAINING SAME AND USES THEREOF - Glycosylated indolocarbazoles, method for obtaining same and uses thereof. This invention relates to rebeccamycin and staurosporine derivatives obtained by fermentation of recombinant bacterial strains. The invention also relates to the methods used to obtain the recombinant strains and the production of rebeccamycin and staurosporine derivatives. The invention also relates to bacterial strains that are of use for the production of rebeccamycin and staurosporine derivatives. Lastly, the rebeccamycin and staurosporine derivatives described herein are applicable to the field of human health, specifically for manufacturing drugs that are of use in the treatment of tumour, neurological and inflammatory diseases.06-09-2011
20100179101Novel Crystalline Forms Of An Antiviral Benzimidazole Compound - The invention relates to crystalline forms of 5,6-dichloro-2-(isopropylamino)-1-β-L-ribofuranosyl-1H benzimidazole, pharmaceutical compositions comprising the same, processes for preparing the same, and their use in medical therapy.07-15-2010
20120302517TET2 AS A NEW DIAGNOSTIC AND PRONOSTIC MARKER IN HEMATOPOIETIC NEOPLASMS - The present invention concerns an in vitro method for diagnosing a myeloid tumour or a lymphoid tumour in a subject, which comprises the step of analyzing a biological sample from said subject by (i) detecting the presence of a mutation in the Ten Eleven Translocation protein family member 2 gene (TET2) coding for the polypeptide having the sequence SEQ ID NO:2, and/or (ii) analyzing the expression of the TET2 gene; wherein the detection of such a TET2 mutation, of the absence of expression of TET2 or of the expression of a truncated TET2 is indicative of a subject developing or predisposed to develop a myeloid tumour or a lymphoid tumour.11-29-2012
20090176721NUCLEOSIDE ANALOGS WITH CARBOXAMIDINE MODIFIED MONOCYCLIC BASE - Novel nucleoside analog compounds are disclosed. The novel compounds or pharmaceutically acceptable esters or salts thereof may be used in pharmaceutical compositions, and such compositions may be used to treat an infection, an infestation, a neoplasm, or an autoimmune disease. The novel compounds may also be used to modulate aspects of the immune system, including modulation of Type 1 and Type 2 activity.07-09-2009
20100029579ANTIVIRAL COMPOUNDS - The invention provides a new class of compounds exhibiting an inhibitory effect on neuraminidase (NA), hemagglutinin (HA) and structural M02-04-2010
20100062992Salts of 5-Azacytidine - The present invention relates to salts of 5-azacytidine as well as methods for synthesizing the salts described herein. Pharmaceutical compositions and methods of using the 5-azacytidine salts are also provided, including methods of administering the salts or pharmaceutical compositions thereof to treat conditions, such as cancer and hematological disorders.03-11-2010
20090105168Use Of HDAC And/Or DNMT Inhibitors For Treatment Of Ischemic Injury - The present invention provides methods of ameliorating or reducing the extent of ischemic injury, reperfusion injury, and myocardial infarction, by administering an inhibitor of histone deacetylase enzyme (HDAC) or an inhibitor of DNA methyltransferase enzyme (DNMT).04-23-2009
20110028419FUNGICIDE COMPOSITION FOR AGRICULTURE AND HORTICULTURE AND METHOD FOR PREVENTING PLANT DISEASES - The present invention provides a composition in which a fungicidal effect against a cultivated crop infected by a plant disease is stable and highly active. An excellent agricultural or horticultural fungicide composition for controlling a plant disease is provided by using (a) at least one imidazole compound represented by formula (I):02-03-2011
20090325895METHODS OF TREATING AN INFLAMMATORY-RELATED DISEASE - The invention relates to pharmaceutical compositions and methods of treating inflammatory-related diseases associated with pro-inflammatory cytokine expression and/or reduced expression of anti-inflammatory cytokines. The method typically comprises administration of one or more compounds selected from isoindigo, indigo, indirubin, or derivatives thereof, such as, Meisoindigo and NATURA. Preferably the pharmaceutical composition comprises one or more compounds selected from isoindigo, indigo, indirubin, or derivatives thereof, an anti-inflammatory agent, and a pharmaceutically acceptable carrier.12-31-2009
201002616673- -D-RIBOFURANOSYLTHIAZOLO[4-5-d]PYRIMIDINE NUCLEOSIDES AND USES THEREOF - The invention is directed to 3-β-D-ribofuranosylthiazolo[4,5-d]pyrimidine nucleosides and pharmaceutical compositions containing such compounds that have immunomodulatory activity. The invention is also directed to the therapeutic or prophylactic use of such compounds and compositions, and to methods of treating diseases and disorders described herein, by administering effective amounts of such compounds.10-14-2010
20110319355METHODS FOR TREATING NON-SMALL CELL LUNG CANCER USING 5-AZACYTIDINE - The present disclosure provides methods for treating subjects having non-small cell lung cancer, wherein the methods comprise administering to the subject a cytidine analog, such as 5-azacytidine. Also provided are methods relating to identification and treatment of particular non-small cell lung cancer types sensitive to particular cytidine analogs.12-29-2011
20120010163NOVEL ANTIBACTERIAL COMPOUNDS, METHODS OF MAKING THEM, AND USES THEREOF - The present invention relates to novel therapeutics with antibacterial activity, processes for their preparation, and pharmaceutical, veterinary and nutritional compositions containing them as active ingredients. The present invention also relates to uses of the novel therapeutics, for example, as medicants or food additives in the treatment of bacterial infections or to aid body mass gain in a subject.01-12-2012
20110166092DOSING METHODS FOR TREATING DISEASE - The invention relates to a method for treating disease such as viral infections, tumors, and cancers, comprising administering a TLR7 agonist or TLR7 agonist prodrug according to a cyclical dosing schedule having a dosing period and a resting period. For example, the method encompasses treating disease with: Formula (I) 5-amino-3-(2′-Q-acetyl-3′-deoxy-β-D-ri-bofuranosyl)-3H-thia-zolo[4,5-d]pyrimidin-2-one Tosylate according to a dosing schedule of every-other-day or a dosing schedule of three consecutive days of dosing followed by four consecutive days of not dosing.07-07-2011
20120022013METHODS AND COMPOSITIONS FOR EXTENDING THE LIFE SPAN AND INCREASING THE STRESS RESISTANCE OF CELLS AND ORGANISMS - The invention provides methods and compositions for modulating the life span of eukaryotic and prokaryotic cells and for protecting cells against certain stresses, e.g., heatshock. One method comprises modulating the flux of the NAD+ salvage pathway in the cell, e.g., by modulating the level or activity of one or more proteins selected from the group consisting of NPT1, PNC1, NMA1 and NMA2. Another method comprises modulating the level of nicotinamide in the cell.01-26-2012
20120157401METHODS FOR TREATING NEUROFIBROMATOSIS - Methods for treating neurofibromatosis involving the administration of a compound that selectively inhibits pathological production of human VEGF are described. The compound can be administered as a single-agent therapy or in combination with one or more additional therapies to a human in need of such treatment.06-21-2012
20120157400METHODS FOR TREATING KAPOSI SARCOMA - Methods for treating Kaposi's sarcoma involving the administration of a compound that selectively inhibits pathological production of human VEGF are described. The compound can be administered as a single-agent therapy or in combination with one or more additional therapies to a human in need of such treatment.06-21-2012
20120157402METHODS FOR TREATING BRAIN TUMORS - Methods for treating brain tumors involving the administration of a compound that selectively inhibits pathological production of human VEGF are described. The compound can be administered as a single agent therapy or in combination with one or more additional therapies to a human in need of such treatment.06-21-2012
20110105424GLUCOPYRANOSIDE COMPOUND - A compound of the formula:05-05-2011
20120135949COMBINATION THERAPY FOR TREATING HCV INFECTION - The present invention relates to therapeutic combinations comprising (a) Compound (1), or a pharmaceutically acceptable salt thereof, as herein described, (b) Compound (2), or a pharmaceutically acceptable salt thereof, as herein described, and optionally (c) ribavirin, and methods of using such therapeutic combinations for treating HCV infection or alleviating one or more symptoms thereof in a patient.05-31-2012
20120178709CRYSTALLINE PHASES OF 5,6-DFICHLORO-2-(ISOPROPYLAMINO)-1- -L-RIBOFURANOSYL)-1H-BENZIMIDAZOLE - The invention relates to novel crystalline phases of 5,6-dichloro-2-(isopropylamino)-1-(β-L-ribofuranosyl)-1H-benzimidazole (Maribavir), pharmaceutical compositions thereof and their use in medical therapy.07-12-2012
20120258926FORMULATIONS OF ACADESINE - This invention provides a buffered solution comprising acadesine, as well as compositions, formulations and kits containing said solution. The solution, compositions, formulation, and kits can be used to prevent morbidity/mortality in a patient or to treat an ischaemic condition, a condition regulated by adenosine, or a condition associated with reduced blood flow to a tissue in a patient.10-11-2012
20120190637COMBINATION THERAPY TREATMENT FOR VIRAL INFECTIONS - Therapeutics which employ a combination of an antiviral agent and an EP4 receptor agonist for the treatment of human respiratory diseases associated with viral infections are described. Viral infections may include an influenza A virus, for example H1N1, H3N2 and H5N1, and mutations thereof, and/or a coronavirus, for example a virus that causes severe acute respiratory syndrome, “SARS”.07-26-2012
20080300200Therapeutic Furopyrimidines and Thienopyrimidines - The invention provides compounds of formula I, II, and III as described herein, as well as pharmaceutical compositions comprising the compounds, and synthetic methods and intermediates that are useful for preparing the compounds. The compounds of formula I, II, and III are useful as anti-viral agents and/or as anti-cancer agents.12-04-2008
20120270827Indole Antiviral Compositions And Methods - The present invention provides novel chemical compounds, and methods for their use. In particular, the present invention provides indole derivatives (e.g. as shown in Formula (I)) and related compounds and methods of using indole derivatives and related compounds as therapeutic agents to treat a number of conditions, including those associated with viral infection and cardiovascular diseases.10-25-2012
20120270826ADULT STEM CELLS, MOLECULAR SIGNATURES, AND APPLICATIONS IN THE EVALUATION, DIAGNOSIS, AND THERAPY OF MAMMALIAN CONDITIONS - The present invention relates to the identification of a stem cell-specific signature or signatures composed of protein and/or nucleic acid markers expressed by virtue of the position of a cell or cells in the time line of its/their development and the impact of the cells' environment on this signature as it relates to the cells' stem cell potential. The composition and combination of these signatures provides a means of identifying, manipulating and differentiating said adult stem cells and thus, their acquisition and utilization in research, diagnosis, and therapy of normal and pathological conditions.10-25-2012
20120277177CRYSTALLINE PHASES OF 5,6-DICHLORO-2-(ISOPROPYLAMINO)-1-BETA-RIBOFURANOSYL-1H-BENZIMIDAZOLE - The invention relates to novel crystalline forms of 5,6-dichloro-2-(isopropylamino)-1-(β-L-ribofuranosyl)-1H-benzimidazole (Maribavir), pharmaceutical compositions thereof and their use in medical therapy.11-01-2012
20130012468CHEMICAL COMPOUNDS - 3-(2′,3′-dideoxy-ribo-β-L-furanosyl)[2,3-d]pyrimidin-2(3H)-one derivatives comprising 6-substitutents on the base moiety are shown to have anti-viral properties, particularly with respect to vaccinia and measles. The compounds have unnatural L ribose stereochemistry.01-10-2013
20110160157METHODS OF TREATING AN INFLAMMATORY-RELATED DISEASE - The invention relates to pharmaceutical compositions and methods of treating inflammatory-related diseases associated with pro-inflammatory cytokine expression and/or reduced expression of anti-inflammatory cytokines. The method typically comprises administration of one or more compounds selected from isoindigo, indigo, indirubin, or derivatives thereof, such as, Meisoindigo and NATURA in an amount less than sufficient to inhibit CDKs.06-30-2011
200802550633-B-D-RIBOFURANOSYLTHIAZOLO[4,5-d]PYRIMIDINE NUCLEOSIDES AND USES THEREOF - The invention is directed to 3-β-D-ribofuranosylthiazolo[4,5-d]pyrimidine nucleosides and pharmaceutical compositions containing such compounds that have immunomodulatory activity. The invention is also directed to the therapeutic or prophylactic use of such compounds and compositions, and to methods of treating diseases and disorders described herein, by administering effective amounts of such compounds.10-16-2008
20090209477AZACYTIDINE ANALOGUES AND USES THEREOF - The present invention is directed toward compounds of Formula (I) as follows:08-20-2009
20130172284USE OF 1-BETA-D-RIBOFURANOSYL-1H-1,2,4-TRIAZOLE-3-CARBOXAMIDE FOR THE TREATMENT OF INFECTIOUS SALMON ANEMIA - The invention relates to the novel use of 1-beta-D-ribofuranosyl-1H-1,2,4-triazole-3-carboxamide for the treatment of infectious salmon anaemia caused by the infectious salmon anaemia or ISA virus in salmonids.07-04-2013
20080274988Microarray-Mediated Diagnosis of Herpes Virus Infection by Monitoring Host's Differential Gene Expression Upon Infection - The present invention discloses disease-associated molecules and assays, which are useful for diagnosing and assessing those animals with herpes virus infection, and determining those animals at risk of developing an herpes virus infection or its sequelae. The invention has practical use in the early diagnosis of disease, in monitoring an animal's immune response to the disease, and in enabling better treatment and management decisions to be made in clinically and sub-clinically affected animals.11-06-2008
20110269706Hydroxamic Acid Derivatives - The disclosure includes hydroxamic compounds of Formula I: (I) wherein P, Z, and m are defined herein. Also disclosed is a method for treating a neoplastic disease or an immune disease with these compounds.11-03-2011
20130116207Compositions and Methods for Treating Cancer - Provided herein are compounds used to inhibit the deamination enzyme responsible for the inactivation of therapeutic compounds, and methods of using them.05-09-2013
20130102557Methods for Treating HCV - The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to the subject effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), an inhibitor of cytochrome P450 (e.g., ritonavir), and ribavirin.04-25-2013
20130116208ADMINISTRATION OF A NEDD8-ACTIVATING ENZYME INHIBITOR AND HYPOMETHYLATING AGENT - The present disclosure relates to methods for the treatment of cancer in patients in recognized need of such treatment. The methods comprise administering to such a patient an NAE inhibitor or a pharmaceutically acceptable salt thereof, such as ((1S,2S,4R)-4-(4-((1S)-2,3-dihydro-1H-inden-1-ylamino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-hydroxycyclopentyl)methyl sulfamate (MLN4924) or {(1S,2S,4R)-4-[(6-{[(1R,2S)-5-chloro-2-methoxy-2,3-dihydro-1H-inden-1-yl]amino}pyrimidin-4-yl)oxy]-2-hydroxycyclopentyl}methyl sulfamate (I-216), and a hypomethylating agent or a pharmaceutically acceptable salt thereof, such as azacitidine or decitabine. Also disclosed are medicaments for use in the treatment of cancer.05-09-2013
20130116206QUINOLINE DERIVATIVES USED AS PET IMAGING AGENTS - There is provided compounds of formula (I), wherein R05-09-2013
20130178439METHODS OF TREATING AN INFLAMMATORY-RELATED DISEASE - The invention relates to pharmaceutical compositions and methods of treating inflammatory-related diseases associated with pro-inflammatory cytokine expression and/or reduced expression of anti-inflammatory cytokines. The method typically comprises administration of one or more compounds selected from isoindigo, indigo, indirubin, or derivatives thereof, such as, Meisoindigo and NATURA. Preferably the pharmaceutical composition comprises one or more compounds selected from isoindigo, indigo, indirubin, or derivatives thereof, an anti-inflammatory agent, and a pharmaceutically acceptable carrier.07-11-2013
20130102556Use of N1,N4-bis[3-(Ethylamino)Propyl]-2-Butene-1,4-Diamine Compounds in Combination with Epigenetic-Acting Pharmaceuticals for Enhanced Cancer Therapy - Combination methods for treatment of cancer and of blood disorders, using PG-11047 ((2Z)-N1,N4-bis[3-(ethy-lammo) propyl]-2-butene-1,4-diamine) and PG-11048 ((2E)-N1,N4-bis[3-(ethylamino)propyl]-2-butene-1,4-diamine) in combination with DNA methyltransferase (DNMT) inhibitors, histone deacetylase (HDAC) inhibitors, or both DNA methyltransferase inhibitors and histone deacetylase inhibitors, are disclosed. Hematopoietic cancers, lung cancers, mesothelioma, cutaneous T-cell lymphoma (CTCL), multiple myeloma, solid tumors, and blood disorders such as myelodysplastic syndromes can be treated using the methods of the invention.04-25-2013
20110275588Fused Diimidazodiazepine Compounds and Methods of Use and Manufacture Thereof - The invention encompasses novel compounds and pharmaceutically acceptable salts thereof and compositions including therapeutically or prophylactically effective amounts of such compounds or pharmaceutically acceptable salts thereof. The invention also encompasses methods for treating or preventing diseases and disorders associated abnormal cell growth, for example, treating or preventing cancer or tumor growth, which methods include administering to a mammal in need thereof a composition comprising a therapeutically or prophylactically effective amount of a compound of the invention or a pharmaceutically acceptable salt thereof.11-10-2011
20100317609Method of Producing Hydroxyalkyl Starch Derivatives - The present invention relates to methods of producing hydroxyalkyl starch (HAS) derivatives having a structure according to formula (I) comprising reacting HAS of formula (I) at its optionally oxidized reducing end or a HAS derivative, obtainable by reacting HAS of formula (I) at its optionally oxidized reducing end with a compound (D) comprising at least one functional group Z12-16-2010
20130157970NOVEL GLYCOSIDE COMPOUNDS - Compounds of formula (I):06-20-2013
20120283210MARIBAVIR ISOMERS, COMPOSITIONS, METHODS OF MAKING AND METHODS OF USING - The invention relates to novel compositions and methods of using maribavir which enhance its effectiveness in medical therapy, as well as to maribavir isomers and methods of use thereof for counteracting the potentially adverse effects of maribavir isomerization in vivo in the event it occurs.11-08-2012
20130190263ORAL VETERINARIAN COMPOSITION FOR SALMONIDS COMPRISING 1-BETA-D-RIBOFURANOSYL-1H-1,2,4-TRIAZOLE-3-CARBOXAMIDE AND USE THEREOF IN THE TREATMENT OF INFECTIOUS ANEMIA IN SALMONIDS - The invention relates to a novel oral veterinary composition for salmonids, comprising 1-beta-D-ribofuranosyl-1H-1,2,4-triazole-3-carboxamide and to the use thereof for the treatment of infectious salmon anaemia (USA) caused by the infectious salmon anaemia or ISA virus in salmonids.07-25-2013
20120046240Method of Producing Hydroxyalkyl Starch Derivatives - The present invention relates to methods of producing hydroxyalkyl starch (HAS) derivatives having a structure according to formula (I) comprising reacting HAS of formula (I) at its optionally oxidized reducing end or a HAS derivative, obtainable by reacting HAS of formula (I) at its optionally oxidized reducing end with a compound (D) comprising at least one functional group Z02-23-2012

Patent applications in class Nitrogen containing hetero ring

Patent applications in all subclasses Nitrogen containing hetero ring